Clinical Trial Update: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques [Phase 2]

View source ↗

Summary

Phase II trial evaluating FOLFIRI plus panitumumab in stage IV colorectal cancer patients selected as mutation-negative for KRAS, PIK3CA, BRAF, and NRAS using u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Panitumumab (panitumumab)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Stage IV Colorectal Cancer | Phase 2 | Status: COMPLETED